Detailed Information on Publication Record
2020
Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma
NOBRE, L., M. ZAPOTOCKY, S. KHAN, K. FUKUOKA, A. FONSECA et. al.Basic information
Original name
Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma
Authors
NOBRE, L., M. ZAPOTOCKY, S. KHAN, K. FUKUOKA, A. FONSECA, T. MCKEOWN, D. SUMERAUER, A. VICHA, W. A. GRAJKOWSKA, J. TRUBICKA, K. K. W. LI, H. K. NG, L. MASSIMI, J. Y. LEE, S. K. KIM, S. ZELCER, A. VASILJEVIC, C. FAURE-CONTER, P. HAUSER, B. LACH, M. L. VAN VEELEN-VINCENT, PJ FRENCH, Meir EG VAN, W. A. WEISS, N. GUPTA, I. F. POLLACK, R. L. HAMILTON, A. A. N. RAO, C. GIANNINI, J. B. RUBIN, A. S. MOORE, L. B. CHAMBLESS, R. VIBHAKAR, Y. S. RA, M. MASSIMINO, R. E. MCLENDON, H. WHEELER, M. ZOLLO, V. FERRUCI, T. KUMABE, C. C. FARIA, Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), S. JUNG, E. LOPEZ-AGUILAR, J. MORA, C. G. CARLOTTI, J. M. OLSON, S. LEARY, J. CAIN, L. KRSKOVA, J. ZAMECNIK, C. E. HAWKINS, U. TABORI, A. N. HUANG, U. BARTELS, P. A. NORTHCOTT, M. D. TAYLOR, S. YIP, J. R. HANSFORD, E. BOUFFET and V. RAMASWAMY (guarantor)
Edition
CELL REPORTS MEDICINE, AMSTERDAM, ELSEVIER, 2020, 2666-3791
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10601 Cell biology
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14110/20:00118572
Organization unit
Faculty of Medicine
UT WoS
000642296600006
Keywords in English
WNT-Activated Medulloblastoma
Tags
International impact, Reviewed
Změněno: 6/5/2021 07:51, Mgr. Tereza Miškechová
Abstract
V originále
Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for therapy de-escalation based on excellent survival; however, a paucity of relapses has precluded additional analyses of markers of relapse. To address this gap in knowledge, an international cohort of 93 molecularly confirmed WNT MB was assembled, where 5-year progression-free survival is 0.84 (95%, 0.763-0.925) with 15 relapsed individuals identified. Maintenance chemotherapy is identified as a strong predictor of relapse, with individuals receiving high doses of cyclophosphamide or ifosphamide having only one very late molecularly confirmed relapse (p = 0.032). The anatomical location of recurrence is metastatic in 12 of 15 relapses, with 8 of 12 metastatic relapses in the lateral ventricles. Maintenance chemotherapy, specifically cumulative cyclophosphamide doses, is a significant predictor of relapse across WNT MB. Future efforts to de-escalate therapy need to carefully consider not only the radiation dose but also the chemotherapy regimen and the propensity for metastatic relapses.